LINC 02086, a novel biomarker for early detection of gastric cancer and a target for cancer therapy.

Gastric cancer (GC) remains a significant global health challenge, often diagnosed at advanced stages due to the absence of reliable early detection biomarkers. In this study, we collected serum samples from multicenter, demonstrating elevated serum levels of LINC 02086 exhibit high diagnostic accuracy. LINC 02086 significantly upregulated in GC tissues, with its expression correlating with poor patient survival. As a driving factor of GC, Helicobacter pylori infection upregulates LINC 02086. Mechanistically, we found METTL3-mediated N6-methyladenosine modification of LINC 02086 promotes GC progression, which upregulates HuR by sponging miRNA-139. We also explored the therapeutic potential of LINC 02086-targeted siRNA delivered via lipid nanoparticles, showing significant inhibition of GC growth and metastasis. These findings position LINC 02086 as a promising serum biomarker for early GC detection and as a potential therapeutic target, paving the way for improved diagnostic and treatment strategies in GC.